Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Wakix

- PMLiVE

Merck wins CHMP recommendation for Ebola vaccine

Has also been granted priority review by FDA

Article: Engaging patient advocacy groups

The key to conducting effective rare disease research

Research Partnership

- PMLiVE

Astellas’ Xospata scores positive CHMP recommendation

Could become a potential option for hard-to-treat leukaemia

- PMLiVE

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list

- PMLiVE

ViiV bags EU okay for new two-drug HIV therapy

Rivals Gilead's Biktarvy

- PMLiVE

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

Company to press ahead with phase 3 trial

- PMLiVE

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

Another obstacle for drug

- PMLiVE

Alexion’s Soliris adds new approval in rare disease NMOSD

First ever drug approved for rare autoimmune disease

- PMLiVE

Acer Therapeutics hit by FDA filing rejection

Shares plunge as regulator calls for new trial

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

- PMLiVE

Boehringer eyes rare disease use for respiratory blockbuster

Would help support respiratory franchise

- PMLiVE

Brexit “having impact on EU drug development”

EMA and UK regulator both affected

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links